News
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...
12d
Clinical Trials Arena on MSNNew data from J&J’s bladder cancer drug-device trial strengthens support for NDAJohnson & Johnson (J&J) has reported more data supporting the efficacy of its intravesical drug release system TAR-200 in ...
The FDA cleared the investigational new drug application of IDE849, a potential first-in-class DLL3-targeted antibody-drug ...
The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.
Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for milsaperidone (Bysanti™) for the treatment of acute ...
The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.
Novo Nordisk NOVO.B-3.93%decrease; red down pointing triangle said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results